Skip to content
Attovia Therapeutics Logo
  • OUR TEAM
    • LEADERSHIP
    • BOARD OF DIRECTORS
    • CLINICAL ADVISORS
  • OUR SCIENCE
    • PIPELINE
    • CLINICAL TRIALS
    • PLATFORM
    • PUBLICATIONS
  • INVESTORS
    • OVERVIEW
    • NEWS & EVENTS
      • NEWS RELEASES
      • EVENTS & PRESENTATIONS
    • CORPORATE GOVERNANCE
      • GOVERNANCE DOCUMENTS
      • LEADERSHIP
      • BOARD
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • SEC FILINGS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
    • IR RESOURCES
      • INVESTOR FAQ’s
      • EMAIL ALERTS
      • INVESTOR CONTACT
  • JOIN US
  • CONTACT US
Previous

Preclinical Characterization of ATTO-2306, a Long-Acting Bispecific Antibody Targeting IL-13 and IL-31 for Type 2 Inflammatory Skin Diseases

By attovia|2026-09-25T20:13:40+00:00September 23, 2026|Comments Off on Preclinical Characterization of ATTO-2306, a Long-Acting Bispecific Antibody Targeting IL-13 and IL-31 for Type 2 Inflammatory Skin Diseases

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

About the Author: attovia

Copyright 2026 Attovia | All Rights Reserved
Attovia and ATTOBODY are trademarks of Attovia Therapeutics, Inc.
Terms of Use | Privacy Notice | Cookie Notice
Consumer Health Data Privacy Notice

Attovia Therapeutics Logo

Copyright 2026 Attovia | All Rights Reserved
Attovia and ATTOBODY are trademarks of Attovia Therapeutics, Inc.
Terms of Use | Privacy Notice | Cookie Notice
Consumer Health Data Privacy Notice

Attovia Therapeutics Logo

Copyright 2026 Attovia | All Rights Reserved
Attovia and ATTOBODY are trademarks of Attovia Therapeutics, Inc.
Terms of Use | Privacy Notice | Cookie Notice
Consumer Health Data Privacy Notice

Attovia Therapeutics Logo
Page load link
Go to Top